BioMedNewsBreaks

WednesdayApr 29, 2026 2:15 pm

BioMedNewsBreaks — Earth Science Tech Inc. (ETST) Leveraging Vertical Integration to Target Precision Medicine Market

Earth Science Tech (OTC: ETST) was featured in a recent article that discussed its efforts to build vertical integration across telemedicine, pharmaceuticals, and clinical services. “At the nucleus of ETST’s model are its compounding pharmacy operations, which produce customized medications tailored for specific patient needs. This segment aims to tackle the growing gap in traditional pharmaceutical manufacturing… Through operating licensed compounding facilities, the company is strategically positioned to serve a niche but quickly evolving market driven by demand for precision treatment and specialized formulations,” reads the publication. “In addition to this, the company’s telemedicine infrastructure operates as a front-end patient acquisition…

Continue Reading

WednesdayApr 29, 2026 10:20 am

BioMedNewsBreaks – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) Files Patent Applications for AI Voice Intoxication Detection Technology

This article has been disseminated on behalf of MindBio Therapeutics Corp. and may include paid advertising. MindBio Therapeutics (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF), a biotechnology company commercializing AI-driven voice technology for drug and alcohol intoxication detection, announced it has filed patent applications for its technology that uses voice and artificial intelligence (“AI”) to detect intoxication. The company said its Edge AI Intoxication Detection Kiosks use more than 50 million data points to predict drug and alcohol intoxication by analyzing the human voice, with commercial testing hardware and software solutions for the mining and aviation industries on track for delivery…

Continue Reading

TuesdayApr 28, 2026 11:54 am

BioMedNewsBreaks — ARMR Sciences Inc. Advances Fentanyl Vaccine with Private Placement Led by Joseph Gunnar & Co.

ARMR Sciences completed a private placement financing with strategic and institutional investors, with Joseph Gunnar & Co., LLC acting as placement agent, as the company advances toward human trials for its fentanyl vaccine. Backed by the U.S. Department of War, the vaccine is designed to prevent fatal overdoses and address threats from substances such as fentanyl, supporting continued development and clinical progression. To view the announcement, visit https://ibn.fm/t39w2 About ARMR Sciences Inc. ARMR Sciences Inc. is America's biodefense technology company, developing next-generation countermeasures against synthetic drug threats, such as fentanyl. Through its foundational license, ARMR is backed by early-stage research funding from the…

Continue Reading

MondayApr 27, 2026 9:00 am

BioMedNewsBreaks – NextPlat Corp (NASDAQ: NXPL, NXPLW) Regains Compliance With Nasdaq Minimum Bid Price Requirement

NextPlat (NASDAQ: NXPL, NXPLW) announced it has regained compliance with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) following receipt of a compliance letter from The Nasdaq Stock Market LLC on April 27, 2026. Nasdaq determined the Company’s shares maintained a closing bid price of at least $1.00 for 10 consecutive business days from April 13, 2026 to April 24, 2026, and confirmed the matter is now closed, with NextPlat continuing to trade on The Nasdaq Capital Market under the ticker NXPL. To view the full press release, visit: https://ibn.fm/RUz3J About NextPlat Corp. NextPlat is a global…

Continue Reading

FridayApr 24, 2026 2:57 pm

BioMedNewsBreaks — LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Unlocking New Potential in Precision Cancer Treatment

LIXTE Biotechnology Holdings (NASDAQ: LIXT) is advancing the precision oncology landscape, developing therapies that complement existing cancer treatments while integrating cutting-edge data solutions. “The company’s lead program, LB-100, is a novel small-molecule compound designed to enhance the efficacy of chemotherapy and radiation, aiming to improve patient outcomes while reducing treatment-related side effects,” reads a recent article. “By focusing on improving the therapeutic index of existing cancer modalities, the company is tackling a recurrent challenge in the field of oncology: maximizing treatment impact while cutting down risks to healthy tissue.” To view the full article, visit https://ibn.fm/EE6ya About LIXTE Biotechnology Holdings Inc. LIXTE…

Continue Reading

FridayApr 24, 2026 2:24 pm

BioMedNewsBreaks — MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Advances Toward Commercial Deployment of AI Solution

Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising. MindBio Therapeutics (CSE: MBIO) (OTCQB: MBQIF) was featured in a recent article that discussed its move toward commercial deployment of its voice-based artificial intelligence platform for detecting drug and alcohol impairment, with a focus on industrial safety applications in South America’s mining sector. The publication reads, “The biotechnology company recently appointed Chilean policy specialist Felipe Leyton to lead commercialization efforts in the region, a move that signals MindBio’s transition from technology development to field implementation in large enterprise environments… Leyton brings experience in national drug policy and…

Continue Reading

FridayApr 24, 2026 1:55 pm

BioMedNewsBreaks — Earth Science Tech Inc. (ETST) Aligns with Next Phase of Telehealth Through Integrated Platform

Earth Science Tech (OTC: ETST) is positioned for opportunity as telehealth evolves from simple video visits into a comprehensive care model. “The company describes itself as a strategic holding company that acquires and actively manages operating businesses in pharmaceuticals, telemedicine, healthcare services, real estate, and selected consumer markets. ETST’s healthcare-related holdings include telemedicine and pharmaceutical operations designed to support a more connected platform approach; in addition, its compounding operations through RxCompoundStore.com and Mister Meds directly align with the expanding digital healthcare segment,” reads a recent article. “Earth Science Tech recently reported that its operations include compounding pharmaceuticals, telemedicine, and real estate…

Continue Reading

FridayApr 24, 2026 11:02 am

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in NetworkNewsAudio Editorial on Pipeline-Driven Valuation 

Oncotelic Therapeutics (OTCQB: OTLC) is featured in a NetworkNewsAudio Audio Press Release titled “When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech,” which highlights how late-stage drug development assets increasingly drive valuation in the biopharma sector. The editorial, supported by analysis from McKinsey & Company, notes that companies tend to realize the majority of value creation as products approach commercialization, reflecting reduced risk and clearer revenue visibility, a trend directly relevant to Oncotelic’s oncology-focused pipeline and strategic development approach. To view the full press release, visit https://ibn.fm/0uj56 About Oncotelic Therapeutics, Inc. Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy…

Continue Reading

FridayApr 24, 2026 10:48 am

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Highlights Partnership Strategy to Advance Pipeline

Oncotelic Therapeutics (OTCQB: OTLC) provided a corporate update emphasizing its partnership-driven strategy to advance its oncology and rare disease pipeline and enhance shareholder value. The company cited its joint venture with GMP Biotechnology, which contributed to a $249.0 million increase in its balance sheet based on an independent third-party valuation, and said it is pursuing additional collaborations to support development and commercialization efforts. Management noted the approach is designed to advance multiple drug candidates in parallel while maintaining capital efficiency and unlocking the value of its intellectual property portfolio. To view the full press release, visit https://ibn.fm/gX9eb About Oncotelic Therapeutics, Inc. Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the…

Continue Reading

FridayApr 24, 2026 9:20 am

BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Announces $2.61M Private Placement and Warrant Inducement 

Scinai Immunotherapeutics (NASDAQ: SCNI) announced it has entered into a securities purchase agreement with institutional and accredited investors for the sale of 5,208,333 ADSs at $0.48 per ADS, along with accompanying Series A and Series B warrants, and separately executed a warrant inducement agreement with an existing investor. The combined transactions are expected to generate approximately $2.61 million in gross proceeds, with closing anticipated on or about April 27, 2026, subject to customary conditions. The company said proceeds will support expansion of its CDMO platform, advancement of customer programs and continued investment in its immunotherapy pipeline. To view the full…

Continue Reading